E. Ruth Plummer

593 total citations
20 papers, 470 citations indexed

About

E. Ruth Plummer is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, E. Ruth Plummer has authored 20 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in E. Ruth Plummer's work include Microtubule and mitosis dynamics (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (3 papers). E. Ruth Plummer is often cited by papers focused on Microtubule and mitosis dynamics (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (3 papers). E. Ruth Plummer collaborates with scholars based in United Kingdom, United States and Canada. E. Ruth Plummer's co-authors include A H Calvert, Alan V. Boddy, Nicola J. Curtin, Melanie Griffin, Margaret von Mehren, Howard A. Burris, Heather A. Wakelee, L Robson, Donald Bissett and James T. Cassidy and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

E. Ruth Plummer

20 papers receiving 463 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Ruth Plummer United Kingdom	13	229	210	94	74	64	20	470
Michael A. Dengler Germany	14	455 2.0×	109 0.5×	143 1.5×	118 1.6×	49 0.8×	24	706
S. Pezzulli United States	10	403 1.8×	352 1.7×	83 0.9×	94 1.3×	34 0.5×	19	704
Matthias Gutekunst Germany	8	276 1.2×	309 1.5×	98 1.0×	58 0.8×	20 0.3×	11	640
Jingcao Huang China	16	515 2.2×	369 1.8×	180 1.9×	111 1.5×	54 0.8×	51	907
Mitchell Keegan United States	12	409 1.8×	252 1.2×	66 0.7×	110 1.5×	24 0.4×	22	802
Isaku Kohama Japan	7	345 1.5×	236 1.1×	229 2.4×	71 1.0×	25 0.4×	10	588
Rang Woon Park South Korea	10	329 1.4×	135 0.6×	125 1.3×	48 0.6×	59 0.9×	12	522
Alessandra Bulotta Italy	14	264 1.2×	406 1.9×	124 1.3×	249 3.4×	52 0.8×	47	695
Elena Luison Italy	15	246 1.1×	166 0.8×	36 0.4×	73 1.0×	48 0.8×	22	532
Timothy A. Yap United Kingdom	8	289 1.3×	200 1.0×	111 1.2×	71 1.0×	44 0.7×	10	568

Countries citing papers authored by E. Ruth Plummer

Since Specialization

Citations

This map shows the geographic impact of E. Ruth Plummer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Ruth Plummer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Ruth Plummer more than expected).

Fields of papers citing papers by E. Ruth Plummer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Ruth Plummer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Ruth Plummer. The network helps show where E. Ruth Plummer may publish in the future.

Co-authorship network of co-authors of E. Ruth Plummer

This figure shows the co-authorship network connecting the top 25 collaborators of E. Ruth Plummer. A scholar is included among the top collaborators of E. Ruth Plummer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Ruth Plummer. E. Ruth Plummer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rae, S., E. Ruth Plummer, Linda Hogarth, et al.. (2023). Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders. Journal of Cancer Research and Clinical Oncology. 149(18). 16355–16363. 1 indexed citations

McAteer, Martina A., James P.B. O’Connor, Dow‐Mu Koh, et al.. (2021). Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers. British Journal of Cancer. 125(11). 1462–1465. 10 indexed citations

Ogle, Laura, R O’Donnell, Nicholas Hayes, et al.. (2015). High‐resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer. 138(1). 206–216. 37 indexed citations

Peethambaram, Prema P., Lynn C. Hartmann, Derek J. Jonker, et al.. (2014). A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Investigational New Drugs. 33(2). 321–331. 21 indexed citations

Elattar, Ahmed, Asima Mukhopadhyay, Paul Cross, et al.. (2011). Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecologic Oncology. 124(1). 142–147. 45 indexed citations

Nutt, J E, Albiruni Ryan Abdul Razak, K O’Toole, et al.. (2010). The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. British Journal of Cancer. 102(3). 553–560. 25 indexed citations

Plummer, E. Ruth, Paul Lorigan, Larry Hayward, et al.. (2010). Plitidepsin (APL) alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM).. Journal of Clinical Oncology. 28(15_suppl). 8537–8537. 1 indexed citations

Clarke, Michelle J., Evan A. Mulligan, Patrick T. Grogan, et al.. (2009). Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular Cancer Therapeutics. 8(2). 407–414. 77 indexed citations

Bradshaw, Tracey D., Malcolm F. G. Stevens, Hilary Calvert, & E. Ruth Plummer. (2009). Abstract B59: Preliminary clinical experiences of Phortress: Putative role for c-MET inhibition in antitumor activity. Molecular Cancer Therapeutics. 8(12_Supplement). B59–B59. 3 indexed citations

10.

Kristeleit, Rebecca, Hilary Calvert, Hendrik‐Tobias Arkenau, et al.. (2009). A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2566–2566. 19 indexed citations

11.

Jones, Christopher J. & E. Ruth Plummer. (2008). PARP inhibitors and cancer therapy — early results and potential applications. British Journal of Radiology. 81(special_issue_1). S2–S5. 13 indexed citations

12.

Zaremba, Tomasz, Michael Cole, Sally A. Coulthard, E. Ruth Plummer, & Nicola J. Curtin. (2008). Poly(ADP-ribose) polymerase-1 (PARP-1) genomics in relation to activity in healthy volunteers and cancer patients. 2 indexed citations

13.

Šikić, Branimir I., Heather A. Wakelee, Margaret von Mehren, et al.. (2007). A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.. Molecular Cancer Therapeutics. 6. 33 indexed citations

14.

Šikić, Branimir I., Heather A. Wakelee, Margaret von Mehren, et al.. (2007). A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. Journal of Clinical Oncology. 25(18_suppl). 14006–14006. 42 indexed citations

15.

Plummer, E. Ruth, et al.. (2006). Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 2027–2027. 13 indexed citations

16.

Plummer, E. Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide. Clinical Cancer Research. 11. 6 indexed citations

17.

Azzabi, Ashraf, E. Ruth Plummer, Melanie Griffin, et al.. (2005). Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. British Journal of Cancer. 92(6). 1006–1012. 19 indexed citations

18.

Boddy, Alan V., E. Ruth Plummer, Julieann Sludden, et al.. (2005). A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules. Clinical Cancer Research. 11(21). 7834–7840. 84 indexed citations

19.

Plummer, E. Ruth, Damian Greene, & J.T. Roberts. (2000). Seminoma Metastatic to the Prostate Resulting in a Rectovesical Fistula. Clinical Oncology. 12(4). 229–230. 12 indexed citations

20.

Plummer, E. Ruth, M. G. Camboni, A. Bernareggi, et al.. (1999). A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact